Practical Considerations for Antibodies in Myeloma

The monoclonal antibodies daratumumab and elotuzumab currently play a prominent role in the management of multiple myeloma (MM). Both have proven to be effective in combination regimens that incorporate other agents with established activity in this disease, and daratumumab monotherapy also has demonstrated great antitumor activity. With the rapid expansion of treatment options for MM in recent years, it is important to understand how best to use daratumumab and elotuzumab in the care of patients with MM. This article aims to provide perspective on this important aspect of MM management through a succinct review of the preclinical and clinical development of daratumumab and elotuzumab, general approaches to management of transplant-eligible and transplant-ineligible patients with MM, determinants of choice of therapy, challenges associated with use of monoclonal antibodies in myeloma, and future directions with monoclonal antibodies in MM. TARGETS OF DARATUMUMAB AND ELOTUZUMAB: CD38 AND SLAMF7 Section: ChooseTop of pageAbstractTARGETS OF DARATUMUMAB AN... <